NCT05653063 ARCHERY - Artificial Intelligence Based Radiotherapy Treatment Planning for Cervical, Head and Neck and Prostate Cancer
| NCT ID | NCT05653063 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University College, London |
| Condition | Cancer of Prostate |
| Study Type | OBSERVATIONAL |
| Enrollment | 990 participants |
| Start Date | 2023-12-07 |
| Primary Completion | 2025-12-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 990 participants in total. It began in 2023-12-07 with a primary completion date of 2025-12-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The aim of this study is to look at whether an Artificial Intelligence (AI) based computer program can automate two components of the radiotherapy treatment pathway to a sufficient quality standard to enable its routine clinical use. The two components include the delineation (outlining) of anatomical areas that are at risk of tumour spread and at risk of radiation damage, and the definition of the position, size and shape of the radiation beams. The AI-based computer programs have been developed to perform tasks that would normally require direct human involvement by oncologists and medical physicists. Proposed advantages include improved treatment accuracy, as well as a reduction in the time (from weeks to minutes) and human resources needed to deliver radiotherapy, which this study will test.
Eligibility Criteria
Inclusion Criteria: 1. Consecutive patients with histologically confirmed head and neck cancers of the oropharynx, larynx, hypopharynx and nasopharynx (Stage I-III) that have given consent for radical radiotherapy. 2. Consecutive histologically confirmed primary cervical cancer patients (Stage IB-IIIB including pelvic node positive) that have given consent for radical radiotherapy. 3. Consecutive histologically confirmed primary prostate cancer patients (T1-4N0M0) that have given consent for radical radiotherapy. 4. Mental capacity to understand and consent to participate in the study. 5. Patients aged ≥18years. Exclusion Criteria: 1. Patients requiring radiotherapy after curative surgery or surgery that is intended to remove as much of the tumour as possible. 2. Patients receiving palliative radiotherapy 3. Patients aged \< 18years.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT05653063 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Cancer of Prostate. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05653063 currently recruiting?
Yes, NCT05653063 is actively recruiting participants. Contact the research team at mrcctu.archery@ucl.ac.uk for enrollment information.
Where is the NCT05653063 trial being conducted?
This trial is being conducted at Kolkata, India, Mumbai, India, Amman, Jordan, Kuala Lumpur, Malaysia and 2 additional locations.
Who is sponsoring the NCT05653063 clinical trial?
NCT05653063 is sponsored by University College, London. The trial plans to enroll 990 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.